(IN BRIEF) Roche announced the publication of pivotal phase III results for its Itovebi™ (inavolisib)-based regimen at the Clinical Trials in Alzheimer’s Disease congress, demonstrating a 57% reduction in the risk of disease progression or death in patients with HR-positive, … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Dr. Komal Jhaveri, Healthcare, HR-Positive Breast Cancer, Itovebi, Levi Garraway, PIK3CA mutation, Roche, safety, Survival Benefits, wellness